Aurobindo Pharma is currently trading at Rs. 532.75, down by 8.25 points or 1.52% from its previous closing of Rs. 541.00 on the BSE.
The scrip opened at Rs. 541.20 and has touched a high and low of Rs. 546.50 and Rs. 527.40 respectively. So far 346162 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 1017.15 on 14-Jun-2021 and a 52 week low of Rs. 514.50 on 25-May-2022.
Last one week high and low of the scrip stood at Rs. 554.80 and Rs. 522.35 respectively. The current market cap of the company is Rs. 31116.27 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 38.30% and 9.86% respectively.
Aurobindo Pharma has reported results for fourth quarter and year ended March 31, 2022.
The company has reported a fall of 8.07% in its net profit at Rs 802.16 crore for the quarter under review as compared to Rs 872.58 crore for the same quarter in the previous year.
Total income of the company decreased by 24.67% at Rs 3,300.54 crore for Q4FY22 as compared Rs 4,381.45 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a fall of 28.09% in its net profit at Rs 576.14 crore for the quarter under review as compared to Rs 801.18 crore for the same quarter in the previous year.
Total income of the company decreased by 3.64% at Rs 5,858.25 crore for Q4FY22 as compared Rs 6,079.60 crore for the corresponding quarter previous year.
For the year ended March 31, 2022, the company has reported a fall of 53.27% in its net profit at Rs 1,454.71 crore as compared to Rs 3112.91 crore for the previous year.
Total income of the company decreased by 27.14% at Rs 11,958.13 crore for year under review as compared to Rs 16,413.54 crore for year ended March 31, 2021.
For the year ended March 31, 2022, on the consolidated basis, the company has reported a fall of 50.37% in its net profit at Rs 2,647.11 crore as compared to Rs 5,333.82 crore for the previous year.
Total income of the company decreased by 5.48% at Rs 23,775.84 crore for year under review as compared to Rs 25,155.47 crore for year ended March 31, 2021.